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Rationale for revision of the agar dilution method 
(standard JSC method)
In 1968, the agar dilution method was established as an 
independent Japanese method for measuring the minimal 
inhibitory concentration (MIC) of antimicrobial agents. 
The method was revised in 1981 by a committee headed by 
Susumu Mitsuhashi. This method has since been used for 
approximately 20 years without further modiﬁ cation. During 
this period, a method prepared by the Clinical and Labora-
tory Standards Institute (CLSI) has been widely accepted 
as the global standard. There are several striking differ-
ences between the Japanese standard method and the CLSI 
method of agar dilution, regarding the concentrations of the 
bacterial suspensions and the antibacterial agents used. 
Because these differences hamper the evaluation and com-
parison of data on an international scale, members of the 
JSC have advocated a revision of the current JSC method.
Committee on Antimicrobial Susceptibility Testing: 
mission statement for agar dilution method of 
measuring MIC
The Committee on Antimicrobial Susceptibility Testing 
(chaired by Ariaki Nagayama; hereafter, the Committee) 
held several discussion meetings and proposed adopting the 
CLSI method as the JSC standard method of agar dilution. 
This proposal was made because the CLSI method is based 
mostly on the information obtained by international coop-
erative studies, and it is practical enough to be adopted as 
a routine procedure at clinical microbiology laboratories in 
Japan. Furthermore, the CLSI method allows the evalua-
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Abstract In 1968, the agar dilution method was developed 
as an independent Japanese method for measuring the 
minimal inhibitory concentration (MIC) of antimicrobial 
agents. As this method differed in a few respects from the 
MIC measurement methods used in other countries, it was 
revised in 1981, by a committee headed by Susumu Mitsu-
hashi, and the revised method (Chemotherapy 29:76–79, 
1981) has been used since then.
In 1979, an agar dilution method for measuring the MIC 
of anaerobes was developed by a committee chaired by 
Nozomu Kosakai (Chemotherapy 27:559–561, 1979). In 
1990, a committee headed by Sachiko Goto approved a 
broth microdilution method for nonfastidious bacteria 
(Chemotherapy 38:102–105, 1990). Later, a committee 
headed by Atsushi Saito examined media that would be 
suitable for nonfastidious bacteria and fastidious bacteria, 
and they endeavored to prepare a broth microdilution 
method for anaerobic bacteria. In this context, a new broth 
microdilution method was proposed at the 40th Annual 
Meeting of the Japanese Society of Chemotherapy (JSC) in 
Nagoya in 1992, and the proposal was adopted as the stan-
dard JSC method after some modiﬁ cation (Chemotherapy 
41: 183–189, 1993).
The agar dilution method has remained unrevised for 
approximately 20 years. A proposal to review this method 
was recently made, and the 2007 Committee on Antimicro-
bial Susceptibility Testing was formed, comprising the JSC 
members listed below. Under the auspices of this commit-
tee, the method revised in 1981 was reviewed in comparison 
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tion and comparison of data on an international scale and 
is compatible with the Japanese testing standard.
However, the Japanese method of agar dilution1 needs 
to be referred to as a comparison when evaluating new data 
obtained with the CLSI method, because abundant data 
have been accumulated with the Japanese method.
The Japanese agar dilution method for anaerobes, which 
focuses on the genus Bacteroides, also requires some modi-
ﬁ cations and additions, including items such as the medium 
for susceptibility testing, method of preparing bacterial 
suspension, method of anaerobic culture, and incubation 
time.
Taking this background into account, the present Com-
mittee decided to adopt the CLSI method of agar dilution2–5 
as one of the standard JSC methods, based on evaluation 
and comparison of its performance with the JSC method 
when used for measuring the MIC of bacteria in general, 
and of anaerobes in particular.
CLSI agar dilution method for measuring MIC1
Organisms covered
The CLSI agar dilution method for measuring MIC1 is 
applicable to the family Enterobacteriaceae, Pseudomonas 
aeruginosa, nonglucose-fermenting bacteria other than 
Pseudomonas aeruginosa, the genus Acinetobacter, Burk-
holderia cepacia, Stenotrophomonas maltophilia, Vibrio 
cholerae, Staphylococcus spp., enterococci, Neisseria gonor-
rhoeae, streptococci other than pneumococci, Neisseria 
meningitides, Helicobacter pylori, and anaerobes.
Media for susceptibility testing
Organisms
The family Enterobacteriaceae, Pseudomonas aeruginosa, 
nonglucose-fermenting bacteria other than Pseudomonas 
aeruginosa, the genus Acinetobacter, Burkholderia cepacia, 
Stenotrophomonas maltophilia, Vibrio cholerae, Staphylo-
coccus spp., and enterococci.
Mueller-Hinton agar (MHA; composition: meat extract 
[300 g], casamino acid [17.5 g], starch [1.5 g), agar [17 g], 
and puriﬁ ed water [1000 ml]) is used as the medium for 
susceptibility testing. To evaluate the activity of oxacillin 
against Staphylococcus spp., MHA supplemented with 2% 
(w/v) sodium chloride is used.
Neisseria gonorrhoeae
GC agar medium with 1% supplement (for stimulation of 
growth) is used.
The composition of the supplement (per l) is: L-cysteine 
(1.1 g), guanine hydrochloride (0.03 g), thiamine hydro-
chloride (3 mg), p-aminobenzoic acid [PABA] (13 mg), 
vitamin B12 (0.01 g), cocarboxylase (0.1 g), nicotinamide 
adenine dinucleotide [NAD] (0.25 g), adenine (1.0 g), 
L-glutamine (10 g), glucose (100 g), and iron (II) nitrate 
(0.02 g).
Streptococci other than pneumococci
MHA supplemented with sheep blood (5% v/v) is used. 
Lysed horse blood is used when sulfonamides are 
assessed.
Neisseria meningitides
MHA supplemented with sheep blood (5% v/v) is used.
Helicobacter pylori
MHA supplemented with sheep blood (5% v/v; collected 
more than 2 weeks previously) is used.
Anaerobes
Brucella agar medium containing hemin (5 mg/ml), vitamin 
K1 (1 mg/ml), and lysed horse blood (5%) is used.
Inoculum preparation for dilution test; turbidity 
standard for inoculum preparation
According to the CLSI method, a bacterial suspension is 
prepared either by a proliferation technique or by a direct 
technique. For each organism, a suspension (108 CFU/ml) is 
prepared both by the proliferation method and by the direct 
colony suspension method or only by the latter method. If a 
108 CFU/ml suspension is to be prepared, a broth for bacte-
rial proliferation or sterile physiological saline is used by 
adjusting the opacity to 0.5 McFarland (equivalent to 1–2 × 
108 CFU/ml if Escherichia coli ATCC 25922 is used) with a 
speciﬁ c nephelometer or macroscopically. If macroscopic 
adjustment is needed, our Committee recommends the use 
of two standard opacity solutions (0.5 and 1 McFarland). 
When organisms assuming a mucoid form (Pseudomonas 
aeruginosa, Klebsiella, etc.) are used, it is difﬁ cult to prepare 
a suspension of 0.5 McFarland opacity. For these organisms, 
the relationship between opacity and bacterial concentra-
tion is determined in advance.
When a 3-mm inoculation pin is used, the suspension 
with 0.5 McFarland opacity is diluted 1 : 10 with sterile broth 
or physiological saline. If a 1-mm pin is used, the suspension 
with 0.5 McFarland opacity is used without dilution.
Proliferation technique
The family Enterobacteriaceae, Pseudomonas aeruginosa, 
nonglucose-fermenting bacteria other than Pseudomonas 
aeruginosa, the genus Acinetobacter, Burkholderia cepacia, 
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Stenotrophomonas maltophilia, Vibrio cholerae, and 
enterococci.
Direct technique
The family Enterobacteriaceae, Pseudomonas aeruginosa, 
nonglucose-fermenting bacteria other than Pseudomonas 
aeruginosa, the genus Acinetobacter, Burkholderia cepacia, 
Stenotrophomonas maltophilia, Vibrio cholerae, Staphy-
lococcus spp., Enterococcus spp., Neisseria gonorrhoeae, 
Staphylococcus spp other than Staphylococcus pneumoniae, 
Neisseria meningitides, and Helicobacter pylori.
Note that Helicobacter pylori should be passaged for 
72 h in blood agar medium and made into a 2 McFarland 
suspension (1 × 107–108 CFU/ml).
The following methods are recommended for preparing 
suspensions of anaerobes:
(1) Bacterial proliferation technique
An adequate number of colonies are inoculated onto thio-
glycolate medium supplemented with hemin and menadi-
one (containing no indicator), followed by incubation at 
35°C–37°C until an appropriate opacity is recorded (for 
6–24 h).
(2) Direct technique
Colonies incubated for 24–48 h in an agar medium appro-
priate for anaerobes are directly suspended in a liquid 
medium for bacterial suspension. This manipulation needs 
to be completed within 30 min after the anaerobic condi-
tions are suspended.
(3) Method for adjusting suspension
Regardless of whether the proliferation technique or the 
direct technique is used, a suspension equivalent in opacity 
to 0.5 McFarland standard solution is ﬁ nally prepared, as a 
rule (opacity needs to be adjusted depending on the organ-
ism; see the rules6 attached to the Report from the Bacterial 
Susceptibility Assessment Committee, Japanese Society of 
Chemotherapy, 1993, Liquid media for bacterial suspen-
sions should be those with a high transparency level (e.g., 
broth for anaerobes) which have been reduced in advance 
or degassed (boiled and cooled rapidly) before use. Each 
suspension is prepared immediately before inoculation.
Method for preparing antibacterial agents
With the CLSI method, antibacterial agents in bulk powder 
need to be obtained from reliable suppliers, accompanied 
by a certiﬁ cate carrying the generic name, lot number, 
potency, and expiration date. Each drug is dissolved in an 
appropriate solvent for that drug. The solution is stored at 
2°C–8°C, as a rule, because the potencies of some drugs 
decrease rapidly. Thus, it should be understood that the 
manipulations are to be carried out immediately after each 
suspension is made. Also, as a rule, the concentration of the 
antibacterial drug solution is set at the level of 1 μg/ml, and 
additional concentration levels are prepared by serial 
multiplications by certain factors (e.g., 128, 64, 32 μg/ml). 
However, depending on the purpose of the test, concentra-
tion levels may be set in different ways.
Preparing agar dilution plates
Media for susceptibility testing are kept warmed at 45°C–
50°C. The antibacterial drug solution is combined with the 
medium at an appropriate ratio in a dish. The mixture is 
thoroughly agitated until it becomes solid. The agar thick-
ness should be 3–4 mm. As a rule, the medium for anaer-
obes is prepared on the day of use and is not stored.
Inoculating agar dilution plates
With the CLSI method, the prepared/diluted bacterial sus-
pension (107 CFU/ml) is inoculated onto the agar surface at 
a concentration of 1–3 × 104 CFU/spot, using a prescribed 
loop, pipette, or other device for inoculation. When a large 
number of test bacteria are inoculated at one time, a metal-
lic pin (usually 3 mm in diameter) is used. As the devices 
used for inoculation are distributed by various companies, 
the amount of inoculation suitable for use with each metal-
lic pin should be checked in advance. Anaerobes should be 
inoculated at a concentration of 1–3 × 105 CFU/spot onto 
the agar surface. Many anaerobes can endure brief expo-
sure to ambient air, and so all such manipulations can be 
carried out under ambient air. Some bacteria or bacterial 
strains require all manipulations to be performed in an 
anaerobic glove box.
Care is needed regarding the following:
(1)  For bacteria in general, inoculation should be per-
formed on one drug-free plate. For anaerobes, inocula-
tion should be performed on two plates (one for control 
of the anaerobic culture and the other for control of the 
aerobic culture) to check the growth of anaerobes and 
contamination by facultative bacteria at the beginning 
and end of bacterial suspension inoculation.
(2)  The bacterial suspension is ﬁ rst inoculated onto the 
plate with the lowest drug concentration and then onto 
plates with higher drug concentrations.
(3)  If the test drug is changed, inoculation onto a drug-free 
medium is performed to conﬁ rm the absence of any 
inﬂ uence from the previously tested drug.
Incubating agar dilution plates
The CLSI method speciﬁ es the conditions and duration of 
culture for each organism.
Organisms
The family Enterobacteriaceae, Pseudomonas aeruginosa, 
nonglucose-fermenting bacteria other than Pseudomonas 
386 
Table 1. Quality control (QC) ranges for antibacterial drugs
Drug Criterion 
range
Staphylococcus 
aureus 
ATCC 29213
(μg/ml)
Enterococcus 
faecalis 
ATCC 29212 
(μg/ml)
Escherichia 
coli ATCC 
25922 
(μg/ml)
Pseudomonas 
aeruginosa 
ATCC 27853 
(μg/ml)
Escherichia 
coli ATCC 
35218 
(μg/ml)
Amikacin CLSI 1–4 64–256 0.5–4 1–4 –
Amoxicillin CLSI – – – – –
Amoxicillin-clavulanic acid CLSI 0.125/0.06–0.5/0.25 0.25/0.125–1/0.5 2/1–8/4 – 4/2–16/8
Ampicillin CLSI 0.5–2 0.5–2 2–8 – –
Ampicillin-sulbactam CLSI – – 2/1–8/4 – 8/4–32/16
Arbekacin JSCa) 0.25–1 16–64 0.5–2 1–4 1–4
Aspoxicillin JSCa) 2–8 2–8 2–8 16–64 –
Astromicin JSCa) 1–4 16–64 2–8 – –
Azithromycin CLSI 0.5–2 – – – –
Azlocillin CLSI 2–8 1–4 8–32 2–8 –
Aztreonam CLSI – – 0.06–0.25 2–8 –
Biapenem JSCa) 0.03–0.125 0.5–2 0.03–0.125 0.5–2 0.03–0.125
Carbenicillin CLSI 2–8 16–64 4–16 16–64 –
Carumonam JSCa) – – 0.06–0.5 1–4 –
Cefaclor CLSI 1–4 – 1–4 – –
Cefamandole CLSI 0.25–1 – 0.25–1 – –
Cefatrizine JSCa) 0.5–2 – 4–16 – –
Cefazolin CLSI 0.25–1 – 1–4 – –
Cefbuperazone JSCa) 8–32 – 0.125–1 – –
Cefdinir CLSI 0.125–0.5 – 0.125–0.5 – –
Cefditoren CLSI 0.25–2 – 0.125–1 – –
Cefepime CLSI 1–4 – 0.015–0.125 1–8 –
Cefetamet CLSI – – 0.25–1 – –
Ceﬁ xime CLSI 8–32 – 0.25–1 – –
Cefmenoxime JSCa) 1–4 – 0.06–0.5 8–32 –
Cefmetazole CLSI 0.5–2 – 0.25–1 >32 –
Cefminox JSCa) 8–32 – 0.25–1 – –
Cefodizime JSCa) 4–16 – – 16–64 –
Cefonicid CLSI 1–4 – 0.25–1 – –
Cefoperazone CLSI 1–4 – 0.125–0.5 2–8 –
Cefoselis JSCa) 0.5–2 – 0.03–0.125 1–4 –
Cefotaxime CLSI 1–4 – 0.03–0.125 8–32 –
Cefotetan CLSI 4–16 – 0.06–0.25 – –
Cefotiam JSCa) 0.5–2 – 0.125–0.5 – 0.06–0.25
Cefoxitin CLSI 1–4 – 2–8 – –
Cefozopran JSCa) 0.5–2 – 0.06–0.25 0.5–2 –
Cefpiramide JSCa) 1–4 – 1–4 1–4 2–8
Cefpirome JSCa) 0.25–1 1–8 0.03–0.125 1–4 <0.5
Cefpodoxime CLSI 1–8 – 0.25–1 – –
Cefprozil CLSI 0.25–1 – 1–4 – –
Cefroxadine JSCa) 1–4 – 2–8 – –
Cefsulodin JSCa) 2–8 – 32–128 1–4 32–128
Ceftaroline CLSI 0.125–0.5 – 0.03–0.125 – –
Ceftazidime CLSI 4–16 – 0.06–0.5 1–4 –
Cefteram JSCa) 2–8 >1 0.125–0.5 32–128 –
Ceftibuten CLSI – – 0.125–0.5 – –
Ceftizoxime CLSI 2–8 – 0.03–0.125 16–64 –
Ceftobiprole CLSI 0.25–1 0.06–0.5 0.03–0.125 1–4 –
Ceftriaxone CLSI 1–8 – 0.03–0.125 8–64 –
Cefuroxime CLSI 0.5–2 – 2–8 – –
Cephalexin JSCa) 1–4 – 8–32 – –
Cephalothin CLSI 0.125–0.5 – 4–16 – –
Chloramphenicol CLSI 2–16 4–16 2–8 – –
Cinoxacin CLSI – – 2–8 – –
Ciproﬂ oxacin CLSI 0.125–0.5 0.25–2 0.004–0.015 0.25–1 –
Clarithromycin CLSI 0.125–0.5 – – – –
Clinaﬂ oxacin CLSI 0.008–0.06 0.03–0.25 0.002–0.015 0.06–0.5 –
Clindamycin CLSI 0.06–0.25 4–16 – – –
Cloxacillin JSCa) 0.25–1 8–32 256–1024 – –
Colistin CLSI – – 0.25–1 0.25–2 –
Dalbavancin CLSI 0.03–0.125 0.03–0.125 – – –
Daptomycin CLSI 0.25–1 1–4 – – –
Dibekacin JSCa) 0.25–2 8–32 0.5–4 0.5–4 –
Dicloxacillin JSCa) 0.125–0.5 8–32 – – –
Dirithromycin CLSI 1–4 – – – –
Doripenem CLSI 0.015–0.06 1–4 0.015–0.06 0.125–0.5 –
Doxycycline CLSI 0.125–0.5 2–8 0.5–2 – –
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Streptococcus 
pneumoniae 
ATCC 49619 
(μg/ml)
Neisseria 
gonorrhoeae 
ATCC 49226 
(μg/ml)
Helicobacter 
pylori 
ATCC 43504 
(μg/ml)
Bacteroides 
fragilis 
ATCC 25285 
(μg/ml)
Bacteroides 
thetaiotaomicron 
ATCC 29741 
(μg/ml)
Clostridium 
difﬁ cile 
ATCC 700057 
(μg/ml)
Eggerthella 
lenta 
ATCC 43055 
(μg/ml)
– – – – – – –
0.03–0.12 – 0.015–0.125 – – – –
0.03/0.015–0.12/0.06 – – 0.25/0.125–1/0.5 0.5/0.25–2/1 0.25/0.125–1/0.5 –
0.06–0.25 – – 16–64 16–64 1–4 –
– – – 0.5/0.25–2/1 0.5/0.25–2/1 0.5/0.25–4/2 0.25/0.125–2/1
– – – – – – –
– – – – – – –
– – – – – – –
0.06–0.25 – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
1–4 – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
0.03–0.25 0.008–0.03 – – – – –
0.015–0.12 – – – – – –
0.03–0.25 0.015–0.06 – – – – –
0.5–2 0.015–0.25 – – – – –
– 0.004–0.03 – – – – –
– – – – – – –
– 0.5–2 – 8–32 32–128 – 4–16
– – – – – – –
– – – – – – –
– – – – – – –
– – – 32–128 32–128 – 32–128
– – – – – – –
0.03–0.12 0.015–0.06 – 8–32 16–64 – 64–256
– 0.5–2 – 4–16 32–128 – 32–128
– – – – – – –
– 0.5–2 – 4–16 8–32 – 4–16
– – – – – – –
– – – – – – –
– – – – – – –
0.03–0.12 0.03–0.125 – – – – –
0.25–1 – – – – – –
– – – – – – –
– – – – – – –
0.008–0.03 – – – – – –
– 0.03–0.125 – – – – –
– – – – – – –
– – – – – – –
0.12–0.5 0.008–0.03 – – 4–16 – 16–64
0.004–0.03 – – – – – –
0.03–0.12 0.004–0.015 – 32–128 64–256 – –
0.25–1 0.25–1 – – – – –
– – – – – – –
0.5–2 – – – – – –
2–8 – – 2–8 4–16 – –
– – – – – – –
– 0.001–0.008 – – – – –
0.03–0.12 – 0.015–0.125 – – – –
0.03–0.12 – – 0.03–0.125 0.06–0.5 – 0.03–0.125
0.03–0.12 – – 0.5–2 2–8 2–8 0.06–0.25
– – – – – – –
– – – – – – –
0.008–0.03 – – – – – –
0.06–0.5 – – – – – –
– – – – – – –
– – – – – – –
0.06–0.25 – – – – – –
0.03–0.12 – – – – 0.5–4 –
0.015–0.12 – – – – – –
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Drug Criterion 
range
Staphylococcus 
aureus 
ATCC 29213
(μg/ml)
Enterococcus 
faecalis 
ATCC 29212 
(μg/ml)
Escherichia 
coli ATCC 
25922 
(μg/ml)
Pseudomonas 
aeruginosa 
ATCC 27853 
(μg/ml)
Escherichia 
coli ATCC 
35218 
(μg/ml)
Enoxacin CLSI 0.5–2 2–16 0.06–0.25 2–8 –
Ertapenem CLSI 0.06–0.25 4–16 0.04–0.015 2–8 –
Erythromycin CLSI 0.25–1 1–4 – – –
Faropenem CLSI 0.03–0.125 – 0.25–1 – –
Fleroxacin CLSI 0.25–1 2–8 0.03–0.125 1–4 –
Flomoxef JSCa) 0.25–1 32–128 0.06–0.25 – –
Fosfomycin CLSI 0.5–4 32–128 0.5–2 2–8 –
Garenoxacin CLSI 0.004–0.03 0.03–0.25 0.004–0.03 0.5–2 –
Gatiﬂ oxacin CLSI 0.03–0.125 0.125–1.0 0.008–0.03 0.5–2 –
Gemiﬂ oxacin CLSI 0.008–0.03 0.015–0.125 0.004–0.015 0.25–1 –
Gentamicin CLSI 0.125–1 4–16 0.25–1 0.5–2 –
Grepaﬂ oxacin CLSI 0.03–0.125 0.125–0.5 0.004–0.03 0.25–2.0 –
Iclaprim CLSI 0.06–0.25 0.004–0.03 1–4 – –
Imipenem CLSI 0.015–0.06 0.5–2 0.06–0.25 1–4 –
Isepamicin JSCa) 1–4 32–128 0.5–2 2–8 0.5–2
Josamycin JSCa) 1–4 2–8 – – –
Kanamycin CLSI 1–4 16–64 1–4 – –
Kitasamycin JSCa) 0.25–1 1–4 – – –
Latamoxef JSCa) 4–16 – 0.125–0.5 8–32 –
Levoﬂ oxacin CLSI 0.06–0.5 0.25–2 0.008–0.06 0.5–4 –
Lincomycin JSCa) 0.25–1 32–128 – – –
Linezolid CLSI 1–4 1–4 – – –
Lomeﬂ oxacin CLSI 0.25–2 2–8 0.03–0.125 1–4 –
Loracarbef CLSI 0.5–2 – 0.5–2 >8 –
Mecillinam CLSI – – 0.03–0.25 – –
Meropenem CLSI 0.03–0.125 2–8 0.008–0.06 0.25–1 –
Methicillin CLSI 0.5–2 >16 – – –
Metronidazole CLSI – – – – –
Mezlocillin CLSI 1–4 1–4 2–8 8–32 –
Micronomicin JSCa) 0.125–1 4–32 0.5–2 2–8 –
Minocycline CLSI 0.06–0.5 1–4 0.25–1 – –
Moxalactam CLSI 4–16 – 0.125–0.5 8–32 –
Moxiﬂ oxacin CLSI 0.015–0.125 0.06–0.5 0.008–0.06 1–8 –
Mupirocin JSCa) 0.125–0.5 32–128 32–128 – –
Nafcillin CLSI 0.125–0.5 2–8 – – –
Nalidixic acid CLSI – – 1–4 – –
Netilmicin CLSI 0.25 4–16 0.5–1 0.5–8 –
Nitazoxanide CLSI – – – – –
Nitrofurantoin CLSI 8–32 4–16 4–16 – –
Norﬂ oxacin CLSI 0.5–2 2–8 0.03–0.125 1–4 –
Oﬂ oxacin CLSI 0.125–1 1–4 0.015–0.125 1–8 –
Oritavancin CLSI 0.5–2 0.125–1 – – –
Oxacillin CLSI 0.125–0.5 8–32 – – –
Panipenem JSCa) 0.03–0.125 0.25–1 0.03–0.125 4–16 –
Pazuﬂ oxacin JSCa) 0.125–0.5 2–8 0.015–0.06 0.5–2 –
Penicillin CLSI 0.25–2 1–4 – – –
Pipemidic acid JSCa) 32–128 >32 1–4 16–64 –
Piperacillin CLSI 1–4 1–4 1–4 1–8 –
Piperacillin-tazobactam CLSI 0.25/4–2/4 1/4–4/4 1/4–4/4 1/4–8/4 0.5/4–2/4
Polymyxin B CLSI – – 0.25–2 0.25–2 –
Pruliﬂ oxacin JSCa) 0.125–0.5 0.25–2 0.008–0.06 0.125–1 –
Quinupristin-dalfopristin CLSI 0.25–1 2–8 – – –
Ramoplanin CLSI – – – – –
Rifampin CLSI 0.004–0.015 0.5–4 4–16 16–64 –
Rifaximin CLSI – – – – –
Rokitamycin JSCa) 0.25–1 1–4 – – –
Roxithromycin JSCa) 0.5–2 2–8 – – –
Sisomicin JSCa) 0.125–1 8–64 0.25–2 0.5–4 –
Sparﬂ oxacin CLSI 0.03–0.125 0.125–0.5 0.004–0.015 0.5–2 –
Spectinomycin CLSI – – – – –
Sulbenicillin JSCa) 2–8 16–64 8–32 16–64 –
Sulfamethoxazole-trimethoprim CLSI 9.5/0.5 9.5/0.5 9.5/0.5 152/8–608/32 –
Sulﬁ soxazole CLSI 32–128 32–128 8–32 – –
Sultamicillin JSCa) 0.25–1 1–4 4–16 – 8–32
Teicoplanin CLSI 0.25–1 0.06–0.25 – – –
Telavancin CLSI 0.125–1 0.125–0.5 – – –
Telithromycin CLSI 0.06–0.25 0.015–0.125 – – –
Table 1. Continued
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Streptococcus 
pneumoniae 
ATCC 49619 
(μg/ml)
Neisseria 
gonorrhoeae 
ATCC 49226 
(μg/ml)
Helicobacter 
pylori 
ATCC 43504 
(μg/ml)
Bacteroides 
fragilis 
ATCC 25285 
(μg/ml)
Bacteroides 
thetaiotaomicron 
ATCC 29741 
(μg/ml)
Clostridium 
difﬁ cile 
ATCC 700057 
(μg/ml)
Eggerthella 
lenta 
ATCC 43055 
(μg/ml)
– 0.015–0.06 – – – – –
0.03–0.25 – – 0.06–0.25 0.25–1 – 0.5–2
0.03–0.12 – – – – – –
0.03–0.25 – – 0.03–0.25 0.125–1 – 1–4
– 0.008–0.03 – – – – –
– – – – – – –
– – – – – – –
0.015–0.06 – – 0.06–0.5 0.25–1 0.5–2 1–4
0.12–0.5 0.002–0.015 – – – – –
0.008–0.03 – – – – – –
– – – – – – –
0.06–0.5 0.004–0.03 – – – – –
0.03–0.12 – – – – – –
0.03–0.12 – – 0.03–0.125 0.125–0.5 – 0.125–0.5
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
0.5–2 – – – – – –
– – – – – – –
0.5–2 – – 2–8 2–8 1–4 0.5–2
– 0.008–0.03 – – – – –
2–8 – – – – – –
– – – – – – –
0.06–0.25 – – 0.03–0.25 0.125–0.5 0.5–4 0.125–1
– – – – – – –
– – 64–256 0.25–1 0.5–2 0.125–0.5 –
– – – 16–64 8–32 – 8–32
– – – – – – –
– – – – – – –
– – – – – – –
0.06–0.25 – – 0.125–0.5 1–4 1–4 0.125–0.5
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – 0.06–0.5 –
4–16 – – – – – –
– – – – – – –
– 0.004–0.015 – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– 0.25–1 – 8–32 8–32 1–4 –
– – – – – – –
– – – 2–8 8–32 4–16 8–32
– – – 0.125/4–0.5/4 4/4–16/4 4/4–16/4 4/4–16/4
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – 0.125–0.5 –
– – – – – – –
– – – – – 0.0039–0.0156 –
– – – – – – –
– – – – – – –
– – – – – – –
– 0.004–0.015 – – – – –
– 8–32 – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – 0.06–0.5 – – – –
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Drug Criterion 
range
Staphylococcus 
aureus 
ATCC 29213
(μg/ml)
Enterococcus 
faecalis 
ATCC 29212 
(μg/ml)
Escherichia 
coli ATCC 
25922 
(μg/ml)
Pseudomonas 
aeruginosa 
ATCC 27853 
(μg/ml)
Escherichia 
coli ATCC 
35218 
(μg/ml)
Tetracycline CLSI 0.125–1 8–32 0.5–2 8–32 –
Ticarcillin CLSI 2–8 16–64 4–16 8–32 –
Ticarcillin-clavulanic acid CLSI 0.5/2–2/2 16/2–64/2 4/2–16/2 8/2–32/2 8/2–32/2
Tigecycline CLSI 0.03–0.25 0.03–0.125 0.03–0.25 – –
Tinidazole CLSI – – – – –
Tizoxanide CLSI – – – – –
Tobramycin CLSI 0.125–1 8–32 0.25–1 0.25–1 –
Tosuﬂ oxacin JSCa) 0.03–0.125 0.125–0.5 – 0.125–0.5 –
Trimethoprim CLSI 1–4 0.125–0.5 0.5–2 >64 –
Trimethoprim-sulfamethoxazole CLSI 0.5/9.5 0.5/9.5 0.5/9.5 8/152–32/608 –
Trospectomycin CLSI 2–16 2–8 8–32 – –
Trovaﬂ oxacin CLSI 0.008–0.03 0.06–0.25 0.004–0.015 0.25–2 –
Vancomycin CLSI 0.5–2 1–4 – – –
a Criterion range tentatively set by the Japanese Society of Chemotherapy (to be used only as reference information)
b Precautions and other details are given in the CLSI Performance standards for antimicrobial susceptibility testing (latest edition)4
Table 1. Continued
aeruginosa, the genus Acinetobacter, Burkholderia cepacia, 
Stenotrophomonas maltophilia, Vibrio cholerae, Staphylo-
coccus spp., and Enterococcus spp.
Culture
Incubation is done under aerobic conditions at 35 ± 2°C for 
16–20 h (conditions can vary depending on the organisms 
and drugs).
(1)  Yersinia pestis is incubated for 24 h, and the genus 
Acinetobacter, Burkholderia cepacia, and Stenotroph-
omonas maltophilia are incubated for 20–24 h.
(2)  Incubation is continued for 24 h, if the susceptibility of 
Staphylococcus spp. to oxacillin and vancomycin is 
being assessed. The temperature during incubation may 
not exceed 35°C when oxacillin-resistant Staphylococ-
cus spp. are to be detected.
(3)  Incubation is continued for 24 h if the sensitivity of 
enterococci to vancomycin is being assessed.
Neisseria gonorrhoeae
Culture
Incubation is done under 5% CO2 at 36 ± 1°C for 20–24 h 
(temperature may not exceed 37°C).
Staphylococcus spp other than 
Staphylococcus pneumoniae
Culture
Incubation is done under aerobic conditions at 35 ± 2°C for 
20–24 h (conditions vary depending on the organisms and 
drugs). Note the following:
(1)  Incubation in the presence of CO2 is permitted, if neces-
sary for growth.
(2)  If CO2 is used, it should be kept in mind that the MIC 
may be affected by CO2 if the test drug is stable in the 
alkaline pH range.
Neisseria meningitides
Culture
Incubated under 5% CO2 at 35 ± 2°C for 20–24 h.
Helicobacter pylori
Culture
Incubated under slightly aerobic conditions at 35 ± 2°C for 
72 h.
Incubation should be carried out under slightly aerobic 
conditions created by a gas generator to which bacteria of 
the genus Campylobacter are adaptable.
Anaerobic bacteria
Culture
Incubation is done under anaerobic conditions at 35–37°C 
for 42–48 h. Note the following:
(1)  The control medium used to check for contamina-
tion by facultative bacteria is incubated under 5% 
CO2.
(2)  An anaerobic glove box or a container for anaerobic 
culture is used.
(3)  The CLSI method speciﬁ es that the CO2 concentration 
be 4%–7% (corresponding to the use of the Gas Pack 
method).
(4)  The CO2 level should be set at approximately 10%, or 
even less, although bacterial growth is stimulated at 
higher CO2 levels.
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Streptococcus 
pneumoniae 
ATCC 49619 
(μg/ml)
Neisseria 
gonorrhoeae 
ATCC 49226 
(μg/ml)
Helicobacter 
pylori 
ATCC 43504 
(μg/ml)
Bacteroides 
fragilis 
ATCC 25285 
(μg/ml)
Bacteroides 
thetaiotaomicron 
ATCC 29741 
(μg/ml)
Clostridium 
difﬁ cile 
ATCC 700057 
(μg/ml)
Eggerthella 
lenta 
ATCC 43055 
(μg/ml)
– 0.25–1 0.125–1.0 0.125–0.5 8–32 – –
– – – 16–64 16–64 16–64 16–64
– – – – 0.5/2–2/2 16/2–64/2 16/2–64/2
– – – 0.125–1 0.5–2 0.125–1 0.06–0.5
– – – – – 0.125–0.5 –
– – – – – 0.06–0.5 –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– 1–4 – – – – –
– 0.004–0.015 – – – – –
– – – – – 0.5–4 –
(5)  When reporting the test results, the CO2 concentration 
used for culture should be documented.
Determining agar dilution end points
The concentration (terminal point) is adopted as the MIC 
when cultures are observed macroscopically under adequate 
illumination, referring to the following criteria:
(1) A concentration at which bacterial growth is markedly 
suppressed and no evident growth is evident.
(2) A concentration at which bacterial growth decreases 
gradually, and only slight growth or haze (traces of the 
inoculated bacterial suspension seen as a group of very 
small spots) is visible.
(3) A concentration at which bacterial growth is markedly 
suppressed but numerous small colonies persist.
(4) A concentration at which bacterial growth is markedly 
suppressed but several colonies of normal size 
persist.
(5) A concentration at which bacterial growth is markedly 
suppressed, but haze can still be seen.
(6) A concentration at which bacterial growth decreases 
gradually and a small number of large colonies are 
visible.
(7) When trimethoprim or any drug of the sulfonamide 
family is tested, an 80% or more decrease in bacterial 
colonies as compared with the control medium is rated 
as “negative.”
Reference strains for quality control
Organisms
Family Enterobacteriaceae
Reference strains for quality control: Escherichia coli ATCC 
25922; Escherichia coli ATCC 35218 is additionally used for 
the assessment of susceptibility to combined drug prepara-
tions containing beta-lactamase inhibitors.
Pseudomonas aeruginosa, nonglucose-fermenting bacteria 
other than Pseudomonas aeruginosa, the genus Acineto-
bacter, Burkholderia cepacia, and Stenotrophomonas 
maltophilia.
Reference strains for quality control: Pseudomonas aerugi-
nosa ATCC 27853 and Escherichia coli ATCC 25922. 
Escherichia coli ATCC 35218 is additionally used for the 
assessment of susceptibility to combined drug preparations 
containing beta-lactamase inhibitors.
Vibrio cholerae
Reference strain for quality control: Escherichia coli ATCC 
25922.
Staphylococcus spp.
Reference strains for quality control: Staphylococcus 
aureus ATCC 29213; Escherichia coli ATCC 35218 is 
additionally used for the assessment of susceptibility to 
combined drug preparations containing beta-lactamase 
inhibitors.
Enterococcus spp.
Reference strain for quality control: Enterococcus faecalis 
ATCC 29212.
Neisseria gonorrhoeae
Reference strain for quality control: Neisseria gonorrhoeae 
ATCC 49226.
Staphylococcus spp other than Staphylococcus 
pneumoniae
Reference strain for quality control: Streptococcus pneu-
moniae ATCC 49619.
Neisseria meningitides
Reference strains for quality control: Streptococcus pneu-
moniae ATCC 49619; Escherichia coli ATCC 25922 is used 
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for assessment of susceptibilities to ciproﬂ oxacin, nalidixic 
acid, and minocycline.
Helicobacter pylori
Reference strain for quality control: Helicobacter pylori 
ATCC 43504.
Anaerobic bacteria
Reference strains for quality control: Bacteroides fragilis 
ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741, 
Eggerthella lenta ATCC 43055, and Clostridium difﬁ cile 
ATCC 700057.
Quality control (QC) range for antibacterial drugs
As a rule, the QC range contained in the CLSI Performance 
standards for antimicrobial susceptibility testing (latest 
edition)4 is used for the agar dilution method. For those 
drugs not listed in the CLSI standards, reference QC ranges 
are shown, together with the CLSI QC range, in Table 1. 
The reference QC ranges can be used solely as reference 
information for the assessment of susceptibilities to anti-
bacterial agents.
When the CLSI QC range is applied, a bias within ± one 
tube range may be deemed as acceptable, but a bias exceed-
ing two tubes requires re-measurement.
The QC range needs to be updated according to the 
latest version of the CLSI standards. Reference QC ranges 
may be subject to change (addition or modiﬁ cation) in the 
future.
Other items
(1)  Measurement of the MIC using the agar dilution method 
should be performed as appropriate, referring to the 
latest version of the CLSI standards.
(2)  When the agar dilution method is applied to the fol-
lowing bacteria and other organisms, not covered 
by the CLSI method, it is advisable to use liquid 
dilution, as described in other CLSI standards (see 
references): Haemophilus inﬂ uenzae, Haemophilus 
parainﬂ uenzae, Streptococcus pneumoniae, Bacillus 
anthracis, Yersinia pestis, Burkholderia mallei, Burk-
holderia pseudomallei, Francisella tularensis, Brucella 
spp., Abiotrophia spp., Granulicatella spp., Aeromonas 
hydrophila Complex, Plesiomonas shigelloides, Bacillus 
spp. (other than B. anthracis), Campylobacter jejuni/
coli, Corynebacterium spp., Erysipelothrix rhusiopath-
iae, HACEK group (see below), Lactobacillus spp., 
Leuconostoc spp., Listeria monocytogenes, Moraxella 
catarrhalis, Pasteurella spp., Pediococcus spp., Vibrio 
spp. (other than V. cholerae). The HACEK group 
includes the genus Haemophilus (H. aphrophilus, H. 
paraphrophilus, H. segnis), Actinobacillus actinomy-
cetemcomitans, Cardiobacterium spp., Eikenella cor-
rodens, and Kingella spp.
(3)  Bacterial strains for precision control are available (not 
free of charge) at Kanto Chemical (Tokyo, Japan).
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